Study reveals link between stalking and heart disease
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
UnitedHealth Stock Soars as Warren Buffett's Berkshire Hathaway Discloses $1.57B Stake
UnitedHealth Group (UNH) stock has been a major underperformer in 2025, with UNH down nearly 50% year-to-date amid rising medical costs, regulatory scrutiny, and a Department of Justice investigation into billing practices. However, the company received a major vote of confidence after the closing bell today, when Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) disclosed a substantial new position in UnitedHealth totaling 5.04 million shares, valued at approximately $1.57 billion. As a result, UNH stock has surged over 8% in after-hours trading. That puts UnitedHealth on pace to challenge its overhead 50-day moving average in Friday's session. The shares haven't closed above this descending trendline since mid-April. More News from Barchart 1 'Strong Buy' Dividend Stock to Buy to Protect Your Portfolio After Hitting 30th 52-Week Low, Is Adobe Too Cheap to Ignore? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Why Did Buffett Buy UNH Stock? Valued at $246 billion by market cap, UnitedHealth maintains its position as America's largest health insurer. Despite operational headwinds, the company has maintained its quarterly dividend of $2.21 per share. UNH now yields approximately 3.25%, demonstrating its commitment to shareholder returns and financial stability. Plus, after its steep selloff this year, the stock's current valuation of 11.5 times projected 2027 earnings is significantly below historical averages - suggesting the market may be pricing in an overly pessimistic outlook. What's the Forecast for UNH Stock? Management anticipates a return to growth in 2026 as premium pricing adjustments take effect to offset higher medical costs, particularly in Medicare Advantage plans. Recent trading sessions have shown signs of positive momentum for UNH, with shares rising approximately 11% over the past 5 days as part of a broader rotation into beaten-down healthcare stocks - though the name remains well off its previous highs. Along with Buffett, Wall Street maintains a generally positive outlook on the beaten-down stock, which has a consensus 'Moderate Buy' recommendation. JPMorgan recently reiterated a 'Buy' rating and set a $310 price target for UNH, suggesting about 14% expected upside potential from Thursday's close. This article was created with the support of automated content tools from our partners at Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever. On the date of publication, Elizabeth H. Volk did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. OS Therapies Contact Information:Investor RelationsHarrison Seidner, PhDWaterSeid PartnersOSTX@ Public RelationsStephanie ChenElev8 New Mediastephanie@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
The celebrity doctor overseeing Medicaid suggested that recipients in the program spend too much time watching TV.
President Donald Trump's favorite celebrity doctor is telling Medicaid recipients to get off their couch. Dr. Mehmet Oz, the Trump-appointed administrator of the Centers for Medicare and Medicaid Services, on Thursday suggested that low-income Americans enrolled in the program are bums who spend their hours watching TV. 'An able-bodied person on Medicaid today watches about 6.1 hours of television or just hangs out, leisure time,' he said on CNBC. 'That's a lot of time.'
